MAGI3 and nonpapillary renal cell carcinoma: Notably, our study suggests that ccRCC patients with MAGI3 levels in the middle to high range (protein H-score ≥ 4 or mRNA level >200 RPKM) may derive substantial benefits from Sunitinib treatment.